Table 3. Clinical characteristics of JN.1* SARS-CoV-2 variant in Maharashtra (n = 279).

Out of 550 JN.1* cases with complete metadata, 279 participants were successfully contacted and included in the clinical study.

Clinical characteristics	Count (%)
1. History of previous infection
Present	41 (14.69%)
Absent	238 (85.31%)
2. Presence of comorbidities
a. Present	49 (17.56%)
i. Diabetes mellitus (DM)	18 (36.73%)
ii. Hypertension (HTN)	12 (24.29%)
iii. Underlying lung disease	04 (8.16%)
iv. Arthritis	01 (2.04%)
v. Tuberculosis	01 (2.04%)
vi. Hypothyroidism	01 (2.04%)
vii. Coronary heart disease (CHD)	01 (2.04%)
viii. HIV/AIDS	01 (2.04%)
ix. DM + HTN	08 (16.33%)
x. DM + underlying lung disease	01 (2.04%)
xi. DM + HTN + CHD	01 (2.04%)
xii. DM + HTN + underlying lung disease	01 (2.04%)
b. Absent	230 (82.44%)
3. Vaccination status
a. Vaccinated	263 (94.26%)
i. One dose	12 (4.56%)
ii. Two doses	151 (57.42%)
iii. Booster dose (precautionary dose)	100 (38.02%)
b. Not vaccinated	14 (5.02%)
c. Data not available	02 (0.72%)
4. Symptom status
a. Symptomatic	266 (95.34%)
b. Asymptomatic	13 (4.66%)
5. Presenting symptoms
a. Fever	156 (55.91%)
b. Cold	187 (67.03%)
c. Cough	114 (40.86%)
d. Breathlessness	15 (5.38%)
e. Headache	28 (15.64%)
f. Fatigue	24 (8.60%)
g. Body ache	27 (9.68%)
h. Diarrhea	02 (0.72%)
i. Sore throat	16 (5.74%)
j. Vomiting	02 (0.72%)
k. Chest pain	01 (0.36%)
l. Loss of taste and smell	01 (0.36%)
m. Joint pain	01 (0.36%)
6. Type of quarantine
a. Home isolation	242 (86.74%)
b. Hospital isolation/hospitalization	37 (13.26%)
7. Treatment
a. Received no treatment	03 (1.075%)
b. Received symptomatic treatment	259 (92.83%)
c. Received oxygen therapy	14 (5.02%)
i. Non-invasive ventilation	09 (64.29%)
ii. Invasive ventilation	05 (35.71%)
d. Received antiviral/steroid with oxygen	03 (1.075%)
8. Outcome
a. Alive	275 (98.57%)
b. Dead	04 (1.43%)